New shot could ease daily struggles for myasthenia gravis patients
NCT ID NCT06447597
First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This study tests a new drug called B007 in 104 people with generalized myasthenia gravis, a condition that causes muscle weakness. Participants receive either B007 or a placebo as a shot under the skin twice a month. The goal is to see if B007 improves daily activities, like walking or eating, better than a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- B007 (a drug given as a shot under the skin)
- What this could lead to
- If it works, this could offer a new treatment option to help people with generalized myasthenia gravis manage their symptoms better.
- What could go wrong
- This is an early-to-mid stage trial with only 104 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Zunyi Medical College
RECRUITINGZunyi, China
-
First People's Hospital of Yunnan Province
RECRUITINGKunming, China
-
Huashan Hospital, Fudan University
RECRUITINGShanghai, China
-
Jiangxi Provincial People's Hospital
RECRUITINGNanchang, China
-
Nanfang Hospital, Southern Medical University
RECRUITINGGuangzhou, China
-
Peking University First Hospital
RECRUITINGBeijing, China
-
Renmin Hospital of Wuhan University
RECRUITINGWuhan, China
-
Shandong Provincial Qianfoshan Hospital
RECRUITINGJinan, China
-
Shandong University Cheeloo College of Medicine
RECRUITINGJinan, China
-
Shandong University Cheeloo College of Medicine
RECRUITINGQingdao, China
-
Shenzhen Hospital of University of Hong Kong
RECRUITINGShenzhen, China
-
Sichuan Provincial People's Hospital
RECRUITINGChengdu, China
-
Tangdu Hospital
RECRUITINGXi'an, China
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, China
-
The First Bethune Hospital of Jilin University
RECRUITINGChangchun, China
-
The Second Affiliated Hospital of Nanchang University
RECRUITINGNanchang, China
-
Tongji Medical College of HUST
RECRUITINGWuhan, China
-
Xiangya Hospital Central South University
RECRUITINGChangsha, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at debilitating muscle weakness
- New hope for myasthenia gravis: experimental drug CNP-106 enters human trials
- New hope for myasthenia gravis patients: experimental drug enters phase 2 trial
- New drug trial aims to ease muscle weakness in rare disease
- New study lets myasthenia gravis patients rate their own symptoms on a new drug
- New CAR-T therapy aims to calm overactive immune system in muscle weakness disease